PMID- 34638615
OWN - NLM
STAT- MEDLINE
DCOM- 20211028
LR  - 20211028
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 22
IP  - 19
DP  - 2021 Sep 24
TI  - Metabolomic Approaches to Investigate the Effect of Metformin: An Overview.
LID - 10.3390/ijms221910275 [doi]
LID - 10275
AB  - Metformin is the first-line antidiabetic drug that is widely used in the 
      treatment of type 2 diabetes mellitus (T2DM). Even though the various therapeutic 
      potential of metformin treatment has been reported, as well as the improvement of 
      insulin sensitivity and glucose homeostasis, the mechanisms underlying those 
      benefits are still not fully understood. In order to explain the beneficial 
      effects on metformin treatment, various metabolomics analyses have been applied 
      to investigate the metabolic alterations in response to metformin treatment, and 
      significant systemic metabolome changes were observed in biofluid, tissues, and 
      cells. In this review, we compare the latest metabolomic research including 
      clinical trials, animal models, and in vitro studies comprehensively to 
      understand the overall changes of metabolome on metformin treatment.
FAU - Kim, Hyun Woo
AU  - Kim HW
AUID- ORCID: 0000-0003-2473-8360
AD  - Center for Marine Biotechnology and Biomedicine, Scripps Institution of 
      Oceanography, University of California San Diego, La Jolla, CA 92093, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210924
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Biomarkers)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Biomarkers/blood/urine
MH  - Diabetes Mellitus, Type 2/blood/drug therapy/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/chemistry/*pharmacology
MH  - Insulin Resistance
MH  - Metabolic Networks and Pathways/drug effects
MH  - Metabolome/*drug effects
MH  - Metabolomics/methods
MH  - Metformin/chemistry/*pharmacology
PMC - PMC8508882
OTO - NOTNLM
OT  - BCAAs
OT  - T2DM
OT  - TCA cycle
OT  - metabolome
OT  - metabolomics
OT  - metformin
COIS- The author declares no conflict of interest.
EDAT- 2021/10/14 06:00
MHDA- 2021/10/29 06:00
PMCR- 2021/09/24
CRDT- 2021/10/13 01:02
PHST- 2021/08/20 00:00 [received]
PHST- 2021/09/21 00:00 [revised]
PHST- 2021/09/22 00:00 [accepted]
PHST- 2021/10/13 01:02 [entrez]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2021/10/29 06:00 [medline]
PHST- 2021/09/24 00:00 [pmc-release]
AID - ijms221910275 [pii]
AID - ijms-22-10275 [pii]
AID - 10.3390/ijms221910275 [doi]
PST - epublish
SO  - Int J Mol Sci. 2021 Sep 24;22(19):10275. doi: 10.3390/ijms221910275.